Artivion held a call to discuss its earnings for the second quarter of 2026.

Oct 12, 2026, 8:05 AM ETResultsRead the original at Benzinga

Good for AORT

Artivion's sales and adjusted EBITDA grew, and FDA approval removes a lengthy review step for new AMDS accounts. Gross margin slipped and cash flow was negative because of acquisition costs, but sales gains and the expanded product range support a stronger outlook.

AORT · Artivion

AI read · Good for AORT

The AI's read

These changes could help Artivion win more hospital accounts and sell more aortic products. NEXUS is planned for U.S. sale in January 2027, so that opportunity is still ahead. Lower gross margins and negative cash flow from acquisition costs are concerns. The sales gains, FDA approval, and expanded product range point to a stronger outlook overall.

Get alerts for AORT

Follow Artivion (AORT) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for AORT

Free on the App Store and Google Play, or on the web.